Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma.

Tumori - 1 Apr 2022

Gökyer Ali, Küçükarda Ahmet, Köstek Osman, Gökmen İvo, Özcan Erkan, Sayın Sezin, Taştekin Ebru, Hacıoğlu Bekir, Erdoğan Bülent, Uzunoğlu Sernaz, Çiçin İrfan

Abstract excerpt

OBJECTIVE: To evaluate clinical and demographic characteristics and the results of cytotoxic treatments of KRASG12C, KRASother, and next-generation sequencing (NGS) panel negative patients. METHODS: NGS data of 1264 patients with non-small cell lung cancer were retrospectively evaluated. Among these patients, the mutation distributions of 1081 patients with metastatic lung adenocarcinoma were analyzed. A total of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 33624577
DOI: 10.1177/0300891621996448

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma.PMID 33624577Read ↗

Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.Semantic proximity Read ↗

Next-Generation Sequencing Reveals Distinct Molecular Patterns in Lung Cancer: KRAS-Driven Adenocarcinoma and Limited Comutations in EGFR-Mutated TumorsSemantic proximity Read ↗

Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.Semantic proximity Read ↗

Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and OpportunitiesSemantic proximity Read ↗

Association of Next Generation Sequencing and Routine Testing With Clinical Outcomes of Advanced Non-small Cell Lung Cancer Patients in a Real-world SettingSemantic proximity Read ↗

Clinical next-generation sequencing in patients with non-small cell lung cancer.Semantic proximity Read ↗

Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study.Semantic proximity Read ↗

Comparison of Targeted Next Generation Sequencing Assays in Non-small cell lung cancer PatientsSemantic proximity Read ↗

Clinicopathological significance of mutation profile detected by next generation sequencing in different metastatic organs of non-small cell lung cancers.Semantic proximity Read ↗

Clinicopathologic features of KRAS G12C-mutated non-small cell lung carcinomas:insights from 279 retrospective cases.Semantic proximity Read ↗

Genomic landscape of stage 0-IA lung adenocarcinoma identified by on-site reflex targeted NGS.Semantic proximity Read ↗

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.